Hypolipidemic Agents

• 

  Subject Areas on Research

  • A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. 
  • A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. 
  • A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative. 
  • A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. 
  • Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. 
  • Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. 
  • Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants. 
  • Antihyperlipidemic activity of amine cyanoboranes, amine carboxyboranes, and related compounds. 
  • Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
  • Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. 
  • Colestipol granules in the colon: macroscopic and microscopic findings. 
  • Combination drug therapy for combined hyperlipidemia. 
  • Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. 
  • Countering clinical inertia in lipid management: Expert workshop summary. 
  • Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. 
  • Dual hepatic metabolism of cerivastatin--clarifications. 
  • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. 
  • Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. 
  • Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. 
  • Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. 
  • Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. 
  • Effect of niacin on atherosclerotic cardiovascular disease. 
  • Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. 
  • Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. 
  • Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. 
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 
  • Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. 
  • Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. 
  • Evidence supporting secondary prevention strategies. 
  • Extended-release niacin for modifying the lipoprotein profile. 
  • Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. 
  • Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. 
  • Fenofibrate - a potential systemic treatment for diabetic retinopathy? 
  • Fenofibrate and diabetic retinopathy. 
  • Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Focal toxicity of oxysterols in vascular smooth muscle cell culture. A model of the atherosclerotic core region. 
  • High-dose statins in acute coronary syndromes. 
  • Hypolipidemic activity of boronated nucleosides and nucleotides in rodents. 
  • Hypolipidemic activity of tetrakis-mu-(trimethylamine-boranecarboxylato)-bis(trimethylamin e- carboxyborane)-dicopper(II) in rodents and its effect on lipid metabolism. 
  • Identification and Characterization of Fenofibrate-Induced Liver Injury. 
  • Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease. 
  • Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. 
  • Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. 
  • Influence of clinical trial participation on subsequent antithrombin use. 
  • Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. 
  • Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation. 
  • Insurance status predicts acuity of thoracic aortic operations. 
  • It's all connected. 
  • JCL roundtable: Lipid treatment targets. 
  • Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. 
  • Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). 
  • Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach. 
  • Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. 
  • Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. 
  • Lipoprotein(a) Testing Patterns in a Large Health System. 
  • Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. 
  • Management of diabetic retinopathy: a systematic review. 
  • Medication oversupply in patients with diabetes. 
  • Mixed messages on systemic therapies for diabetic retinopathy. 
  • N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. 
  • Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Poverty, process of care, and outcome in acute coronary syndromes. 
  • Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. 
  • Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Prescriber Continuity and Disease Control of Older Adults. 
  • Prescriber continuity and medication adherence for complex patients. 
  • Primary Prevention of Heart Failure in Women. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. 
  • Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. 
  • Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. 
  • Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. 
  • Reperfusion for acute myocardial infarction: is the future in plastics? 
  • Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. 
  • Reply: Personalize and Optimize Lipid-Lowering Therapies. 
  • Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. 
  • Safety considerations with gastrointestinally active lipid-lowering drugs. 
  • Safety considerations with niacin therapy. 
  • Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. 
  • Sirolimus monotherapy following Campath-1H induction. 
  • Study protocol: Couples Partnering for Lipid Enhancing Strategies (CouPLES) - a randomized, controlled trial. 
  • Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. 
  • Systemic management of diabetic retinopathy. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. 
  • Temporal changes in the external validity of clinical trials: asymptomatic carotid artery stenosis. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. 
  • The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. 
  • The SLCO1B1*5 genetic variant is associated with statin-induced side effects. 
  • The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids. 
  • The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. 
  • The next 10 years in personalized medicine in cardiology. 
  • The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. 
  • The use of lipid-lowering drugs in children. 
  • Therapy and clinical trials. 
  • Treatment of hyperlipidemia with combined niacin-statin regimens. 
  • Treatment of type III hyperlipoproteinemia. 
  • Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. 
  • Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. 
  • Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. 
  • Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. 
  • Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation. 
  • Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. 
  • Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). 
  • Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). 
  • Using "old" medications to fight new COVID-19: Re-purposing with a purpose. 
  • Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine